MCG vs. HyperInsulinemia/Insulin Resistance/PreDiabetes/Diabetes/Heart Failure and the Ancient Nutrient Sensing System

I have known these since the 90’s when I walked away from Med 2.0 and embarked on my journey to creating MCG

Please share my message below.

Finally, the mainstream acknowledges the following (which I have known since I started the journey of creating MCG in the 90’s):

In US populations, as high as 40% of 45-year-olds will develop heart failure during their lifetime [3]; using the echocardiography measurement standards of less than 30% or even 40%, higher ejection fractions, inadequate biomarker hBNP, and utterly inaccurate 123-year-old EKG to make the end-stage-heart-failure diagnosis, these Americans will face a 75% mortality rate [2] with the medium survival of only two years. Making a definitive heart failure diagnosis is always too little and too late due to a lack of proper diagnostic tools. Medicare spends 30% of its annual budget on paying the costs of treating heart failure patients, and the preventable excess premature deaths keep piling up. Adding insult to injury, the direct cost of the failed, irresponsible, unaccountable, and corrupt “late-stage-sickness-seeking-profiteering,” or the “Med 2.0,” sponsored by the paymasters of the American Medical Industrial Complex, the United States, is 4 trillion dollars. The untimely loss of experienced leaders, workers, productivity, and economic opportunities to families and companies adds another 4 trillion dollars to the direct costs. This wasteful and deadly Med 2.0 carnage needs to stop!

What is The underlying cause of the types of heart failure?

The Metabolic Heart Dysfunction rooted in the upstream HyperInsulinemia/Insulin Resistance/PreDiabets/Diabetes effects, the downstream ancient nutrient sensing pathways, mTOR designed for growth and paradoxically impacting on early death, and/or AMPK designed for survival and intracellular autophagy/garbage cleaning moving on more robust immune defenses, and longevity.

Our solution to solving this deadly and costly systematic problem is the MCG Technology Platform:

The legacy Med 2.0 lacks proper diagnostic tools to detect and quantify metabolic heart dysfunction, among other life-threatening causes, especially in the critical earlier stages where disease reversal is still possible. Again, making a definitive heart failure diagnosis is always too little and too late. Numerous other causes lead to heart failure, such as the infamous “Cardiac Syndrome X,” or likely a mixture of chronic high stress, poorly managed hypertension, hormonal disorders, and metabolic microvascular disease [4], which impacts more women, heavy metal poisoning, infectious agents, alcohol, tobacco, drug abuse, harmful pharmaceuticals, vaccines, cancer radiation/chemotherapy treatments, etc., to name a few, are often missed until disasters strike.

Luckily, our MCG Technology detects the earliest signs of metabolic heart dysfunction, among other causes undetectable, unknown, or unseen to the conventional Med 2.0 people, and enables timely identification of the triggering targets to eliminate and lead to disease reversal at the critical stages to save lives at much lower costs. In these crucial stages, MCG shines and fills the gigantic missing diagnostic information gaping hole for only ten minutes at the bedside. The critical and timely information will lead the clinicians to uncover the root causes and find effective treatments to reverse the disease process. On the positive side, MCG can assist in measuring and monitoring the successful functional reversal of metabolic dysfunction due to insulin resistance or Diabetes following effective lifestyle optimization measures, such as intermittent fasting and various daily dietary and physical activity improvements, objectively and physiologically.

MCG ushers in an era of unprecedented Med 3.0 where early detection and primary prevention are possible; people will live longer, healthier, and wealthier lives!

What are the latest happenings in our world?

A curious cardiologist asks a colleague who uses MCG Technology: ”What difference does MCG make?”

My answer:

“Please tell him that MCG is the only technology that detects, measure quantitatively, and monitor both forms of heart failure:

The “weak” type - increased myocardial compliance

The “stiff” type - decreased myocardial compliance

Among other critical capabilities to measure the supply and demand imbalances due to ANY CAUSE or ANY COMORBILITY functionally and physiologically for the first time in the history of medicine.

Metabolic dysfunctions are the majority of the root causes of most chronic diseases, including but not limited to Diabetes and the devastating ineffective treatments, coronary and cerebral artery disease, hypertension, kidney failure, neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, prion disease, Amyotrophic lateral sclerosis (or ALS, or the Lou Gehrig’s Disease), motor neuron disease, Huntington’s disease, spinal muscular atrophy, and spinocerebellar ataxia, autoimmune disorders, endocrinological disorders, and certain types of cancer, e.g., lymphomas, etc.”

Also, “we believe that the number one cause of death in humans is rooted in metabolic disease, not the overly promoted and emphasized ‘obstructive coronary disease,’ so that interventional cardiologists can sell more coronary angiograms, costly intracoronary balloons, expensive stents, procedures, and ultimately, the big buck Coronary Arterial Bypass Graft surgeries. All these interventions deliver no additional benefits on long-term outcomes and longevity of the patients. There is little difference between the interventions and the conservative medical treatment options, according to the reports from the $100 million and decade-long trial, namely the “Ischemia” trial. [1]”

The Bottomline:

Early detection of Cardiometabolic dysfunctions enables timely lifestyle optimization, necessary optimal medical therapies for disease prevention, and reversal of the cardiovascular effects of insulin resistance. MCG Technology is the key to improving the safe and effective early diagnosis of Cardiometabolic dysfunctions to target the survival of organs down to the ancient nutrient sensing pathways at the cellular level and promote longer and healthier lives for patients for a fraction of the costs the failed legacy med 2.0 demands.

This is a bottom-line full description of how MCG Technology functions. “Anything activates, such as Insulin (hyperinsulinemia), inflammation, oxidative stress, and anything that deactivates the mTOR pathway, such as intermittent fasting, fasting, Metformin, etc., and conversely, anything that activates or deactivates the AMPK pathway is fair game for the MCG to detect, measure, and monitor.” MCG is the tip of the spear to usher in a new world of fundamental digital transformation of medicine, from the corrupt, unaccountable, late-stage-sickness-seeking-profiteering legacy of Med 2.0 to the early-detection-chronic-disease-prevention life-saving, ethical, no-lies, honest cost-efficient Med. 3.0 for everyone! Med 3.0, or burst!

Imagine this: In the new era of Med 3.0, people will live to their rightful ages, much healthier, without suffering from the chronic diseases plaguing the populations of the 20th Century!

Joseph

My message to my people:

These are people’s reactions and questions to the above description plus my answers:

References:

1. The ischemia trial: https://www.ischemiatrial.org/

2. Heart Failure Stats

   

   Median Survival of Patients Hospitalized with HF

   The study analyzed data from the GWTG-HF (Get With The Guidelines–HF) registry and claims data from the US Centers for Medicare and Medicaid Services (CMS) and thus examined data from 39,982 patients from 254 hospitals admitted for HF between 2005 and 2009. 

   These patients, who were all fee-for-service Medicare beneficiaries age ≥65 years hospitalized with a diagnosis of HF, were divided by HF subgroup:

   1. 18,299 (45.8%) had HFpEF

   2. 3,285 (8.2%) had HFbEF

   3. 18,398 (46.0%) had HFrEF

3. 40% of the 45-year-olds will develop heart failure, according to NIH.

4. The Cardiac Syndrome X

“The only way of discovering the limits of the possible is to venture past them and explore the impossible.” - Arthur C. Clarke.                                             

Joseph T. Shen, a recovered physician,

Founded Computational BioCybernetics & Lagrangian Mechanics Systems Engineering Technologies 

Researcher and Technology Developer

Managing Member

Premier Heart, LLC

Premier Heart International, LLC

Premier Heart Japan, Inc.

Emergency MCG USA, Inc.

110 Main Street, Suite 201-88

Port Washington, NY 11050

Tel: 516-883-3383 ex 8102

Fax: 516-883-5812 

Mobile: 516-603-6368 (Please alert me who you are with a text message first; please do not respond to unknown numbers. I WILL respond as soon as possible.)

Email: jtshenmd@premierheart.com

The message is often dictated, so my apologies for the errors and typos.

IMPORTANT: This transmission is sent on behalf of Premier Heart, LLC; it may be privileged, proprietary, or confidential. It is intended only for the intended recipient. Suppose you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient. In that case, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received the communication in error, notify us immediately at (516) 883-3383 or by facsimile transmission at (516) 883-5812, and please dispose of and delete this transmission. Thank you.